Lampalizumab

Phase 3Terminated

0 views this week 0 watching💤 Quiet

Interest: 32/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Geographic Atrophy

Conditions

Geographic Atrophy

Trial Timeline

Oct 6, 2014 → Jan 23, 2018

NCT ID

NCT02247531

About Lampalizumab

Lampalizumab is a phase 3 stage product being developed by Roche for Geographic Atrophy. The current trial status is terminated. This product is registered under clinical trial identifier NCT02247531. Target conditions include Geographic Atrophy.

What happened to similar drugs?

1 of 11 similar drugs in Geographic Atrophy were approved

Approved (1) Terminated (2) Active (8)

✅avacincaptad pegolAstellas PharmaApproved

🔄avacincaptad pegolAstellas PharmaPhase 3

🔄Avacincaptad Pegol + ShamAstellas PharmaPhase 3

❌LampalizumabRochePhase 3

🔄Tinlarebant + PlaceboBelite BioPhase 3

🔄APL-2 + APL-2Apellis PharmaceuticalsPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (3)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02745119	Phase 3	Terminated	Jul 21, 2016	Jan 31, 2018	Geographic Atrophy
NCT02247531	Phase 3	Terminated	Oct 6, 2014	Jan 23, 2018	Geographic Atrophy
NCT02247479	Phase 3	Terminated	Sep 18, 2014	Jan 29, 2018	Geographic Atrophy

Competing Products

20 competing products in Geographic Atrophy

See all competitors

Product	Company	Stage	Hype Score
avacincaptad pegol	Astellas Pharma	Phase 3	40
Avacincaptad Pegol	Astellas Pharma	Phase 2/3	38
avacincaptad pegol	Astellas Pharma	Approved	50
Avacincaptad pegol (ACP)	Astellas Pharma	Pre-clinical	33
Avacincaptad Pegol + Sham	Astellas Pharma	Phase 3	40
ABBV-6628 + SYFOVRE	AbbVie	Phase 1/2	39
FWY003 + Placebo	Novartis	Phase 2	42
CLG561 + LFG316 + Sham injection	Novartis	Phase 2	35
LFG316 + Sham + LFG316 Lower dose	Novartis	Phase 2	35
Lampalizumab	Roche	Phase 3	32
Lampalizumab	Roche	Phase 3	32
RO7669330 + Syfovre™ + Izervay™	Roche	Phase 1	36
RO7303359	Roche	Phase 1	29
SAR446597 + Sham Comparator	Sanofi	Phase 1/2	39
Pozelimab	Regeneron Pharmaceuticals	Phase 1	36
IONIS-FB-Lrx + Placebo (sterline saline 0.9%)	Ionis Pharmaceuticals	Phase 2	24
Tinlarebant + Placebo	Belite Bio	Phase 3	41
Pegcetacoplan	Apellis Pharmaceuticals	Pre-clinical	24
APL-2 + APL-2	Apellis Pharmaceuticals	Phase 3	34
APL-2, Pegcetacoplan	Apellis Pharmaceuticals	Phase 3	34